Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
GCTS
4951
GCT Semiconductor Holding
GCTS
$207M
| $95 | ﹤0.01% |
64
-8,435
| -99% | -$11.4K |
2024 Q2
4 quarters
|
|
4952
Unusual Machines
UMAC
$1.12B
| $94 | ﹤0.01% |
+11
| New | +$69 |
2025 Q2
0 quarters
|
|
4953
Fathom Holdings
FTHM
$11.4M
| $89 | ﹤0.01% |
72
| – | – |
2022 Q1
13 quarters
|
|
4954
Immunic
IMUX
$109M
| $86 | ﹤0.01% |
12
-5,617
| -100% | -$51.6K |
2024 Q4
2 quarters
|
|
4955
Dyadic International
DYAI
$18.3M
| $71 | ﹤0.01% |
72
| – | – |
2020 Q2
20 quarters
|
|
|
AFMD
4956
DELISTED
Affimed
AFMD
| $66 | ﹤0.01% |
863
-6,653
| -89% | -$4.47K |
2015 Q2
40 quarters
|
|
|
MPTI.WS
4957
DELISTED
M-tron Industries Warrants
MPTI.WS
| $66 | ﹤0.01% |
+63
| New | +$72 |
2025 Q2
0 quarters
|
|
4958
Tenax Therapeutics
TENX
$74.1M
| $63 | ﹤0.01% |
+11
| New | +$64 |
2025 Q2
0 quarters
|
|
|
SOND
4959
DELISTED
Sonder
SOND
| $62 | ﹤0.01% |
+23
| New | +$47 |
2025 Q2
0 quarters
|
|
|
LPBBW
4960
Launch Two Acquisition Corp Warrant
LPBBW
$1.97M
| $62 | ﹤0.01% |
390
| – | – |
2024 Q4
2 quarters
|
|
4961
Ramaco Resources Class B
METCB
$276M
| $57 | ﹤0.01% |
8
-6,436
| -100% | -$46.8K |
2023 Q2
8 quarters
|
|
4962
Invesco DB US Dollar Index Bullish Fund
UUP
$426M
| $54 | ﹤0.01% |
2
| – | – |
2023 Q1
9 quarters
|
|
4963
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$23.6B
| $53 | ﹤0.01% |
1
| – | – |
2024 Q4
2 quarters
|
|
4964
Biodesix
BDSX
$292M
| $51 | ﹤0.01% |
9
-2,763
| -100% | -$22.3K |
2023 Q4
6 quarters
|
|
4965
iShares 10+ Year Investment Grade Corporate Bond ETF
IGLB
$2.48B
| $50 | ﹤0.01% |
1
| – | – |
2024 Q4
2 quarters
|
|
|
MODV
4966
DELISTED
ModivCare
MODV
| $43 | ﹤0.01% |
14
-12,401
| -100% | -$22.8K |
2022 Q1
13 quarters
|
|
4967
Taylor Devices
TAYD
$177M
| $43 | ﹤0.01% |
1
-3,150
| -100% | -$112K |
2024 Q2
4 quarters
|
|
4968
VirnetX Holding Corp
VHC
$44M
| $43 | ﹤0.01% |
4
| – | – |
2017 Q1
33 quarters
|
|
|
NXU
4969
DELISTED
Nxu, Inc. Class A Common Stock
NXU
| $43 | ﹤0.01% |
+390
| New | +$1.01K |
2025 Q2
0 quarters
|
|
|
XTKG
4970
DELISTED
X3 Holdings Co., Ltd. Class A Ordinary Shares
XTKG
| – | – |
0
| – | – |
2023 Q4
6 quarters
|
|
|
CARM
4971
DELISTED
Carisma Therapeutics
CARM
| $39 | ﹤0.01% |
100
-549,205
| -100% | -$147K |
2023 Q2
8 quarters
|
|
|
PRPH
4972
DELISTED
ProPhase Labs
PRPH
| $39 | ﹤0.01% |
10
-1,247
| -99% | -$4.17K |
2025 Q1
1 quarter
|
|
4973
Quince Therapeutics
QNCX
$29.7M
| – | – |
0
| – | – |
2025 Q2
0 quarters
|
|
4974
Tenaris
TS
$28.3B
| $37 | ﹤0.01% |
1
-35,274
| -100% | -$1.21M |
2022 Q1
13 quarters
|
|
|
LUCK
4975
Lucky Strike Entertainment
LUCK
$721M
| $37 | ﹤0.01% |
4
-4,628
| -100% | -$41.8K |
2022 Q2
12 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.